BIOA
BioAge Labs, Inc.
Key Financials
Operating Income
$-92780000
↓ 18.7%
Shareholders' Equity
$272.1M
↓ 15.8%
Total Liabilities
$22.8M
↓ 34.9%
EPS (Diluted)
$-2.24
↑ 66.2%
Total Assets
$294.9M
↓ 17.7%
Cash & Equivalents
$188.9M
↓ 46.7%
Operating Cash Flow
$-81627000.00
↓ 58.4%
Long-term Debt
$0.00
↓ 100.0%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 7/1/2026 | View on SEC |
| 144 | 6/30/2026 | View on SEC |
| 144 | 6/29/2026 | View on SEC |
| 4 | 6/12/2026 | View on SEC |
| 4 | 6/12/2026 | View on SEC |
| 4 | 6/12/2026 | View on SEC |
| 4 | 6/12/2026 | View on SEC |
| 4 | 6/12/2026 | View on SEC |
| 4 | 6/12/2026 | View on SEC |
| 8-K | 6/12/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | BIOA |
| Company Name | BioAge Labs, Inc. |
| CIK | 1709941 |
| Sector | Pharmaceutical Preparations |
| Industry | Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 510-806-1445 |